Explanation to Bollinger's Bands

Bollinger Bands was created by John Bollinger in the early 1980s, its purpose is to define price action relative to the assets highs and lows. This technical indicator is used to identify buy and sell signals and has proven very well in doing so.

Bollinger Bands consist of a set of three curves drawn in relation to securities prices. The middle band is a measure of the intermediate-term trend, usually a simple moving average, that serves as the base for the upper and lower bands. The interval between the upper and lower bands and the middle band is determined by volatility, typically the standard deviation of the same data that were used for the average. StockInvest.us uses Bollingers suggested 20 day average.

Middle Bollinger Band = 20-period simple moving average
Upper Bollinger Band = Middle Bollinger Band + 2 * 20-period standard deviation
Lower Bollinger Band = Middle Bollinger Band - 2 * 20-period standard deviation

BandWidth defines the current width of the band.
%b defines the current position within the band.

BandWidth = (Upper Bollinger Band - Lower Bollinger Band) / Middle Bollinger Band
%b = (Last - Lower Bollinger Band) / (Upper Bollinger Band - Lower Bollinger Band)

Live Samples:

Bollinger Bottleneck Buy Pattern 1
Bollinger Bottleneck Buy Pattern 2
Bollinger Bottleneck Sell Pattern

Bottlenecks in bandwidth indicate an upcoming change. Break up through the moving average line or continuous movements above the moving average line indicate a break up, and vice versa.

Source: http://www.bollingerbands.com

RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of 4564.T
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

High volatility in OncoTherapy Science,Inc. stock price on Wednesday which ended trading at JP¥18.00
(Updated on May 01, 2024)

Sell candidate since Apr 19, 2024 Loss -5.26% PDF

The OncoTherapy Science,Inc. stock price gained 5.88% on the last trading day (Wednesday, 1st May 2024), rising from JP¥17.00 to JP¥18.00. During the last trading day the stock fluctuated 12.50% from a day low at JP¥16.00 to a day high of JP¥18.00. The price has been going up and down for this period, and there has been a -10% loss for the last 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 2 million more shares were traded than the day before. In total, 5 million shares were bought and sold for approximately JP¥83.26 million.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -5.59% during the next 3 months and, with a 90% probability hold a price between JP¥15.88 and JP¥21.00 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

4564.T Signals & Forecast

A buy signal was issued from a pivot bottom point on Friday, April 26, 2024, and so far it has risen 5.88%. Further rise is indicated until a new top pivot has been found. Volume is rising along with the price. This is considered to be a good technical signal. Some negative signals were issued as well, and these may have some influence on the near short-term development. The OncoTherapy Science,Inc. stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at JP¥18.14 and JP¥19.89. A break-up above any of these levels will issue buy signals. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD).

Support, Risk & Stop-loss for OncoTherapy Science,Inc. stock

On the downside, the stock finds support just below today's level from accumulated volume at JP¥17.00. With no support from accumulated volume below today's level the risk is increased, as a drop below the support at JP¥ may give a huge drop in the stock price.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved JP¥2.00 between high and low, or 12.50%. For the last week, the stock has had daily average volatility of 8.19%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (4564.T) For The Upcoming Trading Day Of Thursday 2nd

For the upcoming trading day on Thursday, 2nd we expect OncoTherapy Science,Inc. to open at JP¥17.33, and during the day (based on 14 day Average True Range), to move between JP¥16.55 and JP¥19.45, which gives a possible trading interval of +/-JP¥1.45 (+/-8.07%) up or down from last closing price. If OncoTherapy Science,Inc. takes out the full calculated possible swing range there will be an estimated 16.13% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at JP¥19.00 (5.56%) than the support at JP¥17.00 (5.56%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is OncoTherapy Science,Inc. stock A Buy?

OncoTherapy Science,Inc. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -2.485 Sell Candidate Unchanged

Predicted Opening Price for OncoTherapy Science,Inc. of Thursday, May 2, 2024

Fair opening price May 2, 2024 Current price
JP¥17.33 ( 3.70%) JP¥18.00

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for 4564.T

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 19.33 7.41 %
R2 18.57 3.16 %
R1 18.10 0.541 %
Current price: 18.00
Support S1 16.57 -7.95 %
S2 16.10 -10.57 %
S3 15.33 -14.81 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 21.00 16.67 %
R2 20.00 11.11 %
R1 19.00 5.56 %
Current price 18.00
Support S1 17.00 -5.56%
S2 0 .
S3 0 .

FAQ

What is the symbol for OncoTherapy Science,Inc. Stock and on which exchange is it traded?
The symbol for OncoTherapy Science,Inc. is 4564.T and it is traded on the TYO (Tokyo Stock Exchange).

Should I buy or sell OncoTherapy Science,Inc. Stock?
OncoTherapy Science,Inc. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

How to buy OncoTherapy Science,Inc. Stock?
OncoTherapy Science,Inc. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy OncoTherapy Science,Inc. Stock.

What's the current price of OncoTherapy Science,Inc. Stock?
As of the end of day on the May 01, 2024, the price of an OncoTherapy Science,Inc. (4564.T) share was JP¥18.00.

What is the 52-week high and low for OncoTherapy Science,Inc. Stock?
The 52-week high for OncoTherapy Science,Inc. Stock is JP¥45.00 and the 52-week low is JP¥16.00.

What is the market capitalization of OncoTherapy Science,Inc. Stock?
As of the May 01, 2024, the market capitalization of OncoTherapy Science,Inc. is 3.918B.

When is the next earnings date for OncoTherapy Science,Inc.?
The upcoming earnings date for OncoTherapy Science,Inc. is May 10, 2024.
Click to get the best stock tips daily for free!

About OncoTherapy Science,Inc.

OncoTherapy ScienceInc. OncoTherapy Science, Inc. researches and develops anti-cancer medicines and therapies in Japan. Its clinical development product pipeline includes small-molecule drugs, such as OTS167, a maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a T-LAK cell-originated protein kinase inhi... 4564.T Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT